Stiefel Laboratories acquires dermal filler developers

Stiefel Laboratories has announced that it is to purchase ABR Invent and ABR Development, the developers of the Atlean dermal filler.

The firm will buy all the shares of the companies through a definitive stock purchase agreement and plans to launch Atlean in a number of worldwide territories over the next 18 months.

Atlean uses a combination of tricalcium phosphate particles suspended in a hyaluronic acid gel and the substance is recommended for remodelling and sculpting the face.

Stiefel Laboratories said that the use of dermal fillers is growing at a rapid pace worldwide, with the firm looking to expand its portfolio in order to offer a wider range of options to its physician partners.

The company also announced plans to develop other products from the ABR portfolio.

Charles W Stiefel, chairman and chief executive officer of the firm, said: “Stiefel Laboratories has been looking for the right dermal filler to add to our aesthetic portfolio for quite some time.”

He said that the innovation, expertise and product portfolio available at ABR Development will significantly improve the company’s position in the global aesthetics market.

In March 2008, Stiefel Laboratories announced the promotion of Wayne Wilson and Michael DiFiore to vice-president of US sales and executive director of managed markets.